

Unaudited Financial Results for the Quarter and Half year Ended September 30, 2018

Particulars	Amount in Lacs except Per Share data											
	3 Months Ended			Quarter Ended			Half Year Ended			Year Ended		
	Un-audited	30-Sep-18	30-Sep-17	Un-audited	30-Jun-18	30-Sep-17	Un-audited	30-Sep-18	30-Sep-17	Un-audited	30-Sep-17	31-Mar-18
<b>1 INCOME</b>												
Revenue from Operations	202.67	178.22	193.98				380.89	333.99				689.98
Other Income	2.24	1.39	5.63				3.63	3.93				11.93
	204.907	179.61	199.61				384.52	337.92				701.91
<b>2 EXPENSES</b>												
(a) Cost of Material Consumed	138.74	112.42	119.09				251.16	194.97				476.74
(b) Purchase of Stock-In-Trade	0.00	0.00	9.28				0.00	9.28				9.23
(c) Changes in Inventories of Finished Goods, Work-In-Progress and Stock-In-Trade	-2.12	2.99	18.37				0.87	13.95				(12.71)
(d) Employee Benefit Expense	22.31	20.06	19.96				42.37	39.87				79.99
(e) Finance Cost	0.38	1.19	0.55				1.57	1.49				11.26
(f) Depreciation, Depletion and Amortisation Expense	3.91	3.40	3.00				7.31	7				13.61
(g) Other Expense	31.05	29.37	22.49				60.42	57.6				90.76
1												
2												
3												
4												
5												
<b>Total Other Expenses</b>	31.05	29.37	22.49				60.42	57.6				90.76
<b>Total Expenses</b>	194.27	169.43	192.74				363.70	324.16				668.88
<b>Total Profit before Exceptional Items and Tax</b>	10.63	10.19	6.87				20.82	13.76				33.03
4 Exceptional Items	0	0.00	0.00				0	0				0
5	10.63	10.19	6.87				20.82	13.76				33.03
6 Tax Expense												
7 Current Tax	2.31	2.29	1.71				4.60	3.604				8.71
8 Deferred Tax	0.00	0.00	0.00				0	0				(0.46)
9	2.31	2.29	1.71				4.60	3.604				8.25
10												
Net Movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0.00	0.00	0.00				0	0				0
<b>Net Profit Loss for the period from continuing operations</b>	8.32	7.90	5.16				16.22	10.16				24.78





**NOTES**

1. The above Financial Results were reviewed by the Audit Committee and thereafter were approved and taken on record by the Board of Directors in their meeting held on November 13, 2018.
2. The Limited Review of the results has been completed by the Statutory Auditors of the Company.
3. As per Indian Accounting Standard (IndAS) "Operating Segment", the Company's business falls within a single business segment viz. "Pharmaceutical Business".
4. The financial results for the quarter and half year ended 30th September, 2018 are also Ind AS compliant. The management has exercised necessary due diligence to ensure that the financial results give a true and fair view. This information has not been subjected to limited review or audit.
5. Previous quarter's amounts have been re-grouped/re-classified, wherever considered necessary to make them comparable with those of the current quarter.
6. Results are available at Company's website [www.ishitadrugs.com](http://www.ishitadrugs.com) and also at [www.bseindia.com](http://www.bseindia.com).

For, **ISHITA DRUGS AND INDUSTRIES LIMITED**



Place **Ahmedabad**  
Date **13-Nov-18**

**JAGDISH AGRAWAL**  
**MANAGING DIRECTOR**  
DIN: 01031687

**ISHITA DRUGS AND INDUSTRIES LIMITED**  
**CIN: L24231GJ1992PLC017054**  
Registered Office: Survey No. 179/1, Village : Vasna-Iyava, Ta. Sanand  
Ahmedabad – 382170  
Website: www.ishitadrugs.com  
Contact: +91 9228016100

**Statement of Assets and Liabilities**

Amount in ₹

Particulars	Half Year Ended	Previous Year Ended	
	6 Months Ended	12 Months Ended	
	Unaudited	Audited	
	30-Sep-18	31-Mar-18	
<b>ASSETS</b>			
1	<b>Non-current assets</b>		
	Property, plant and equipment	11401773	11879886
	Capital work-in-progress		
	Investment property		
	Goodwill		
	Other intangible assets		
	Intangible assets under development		
	Biological assets other than bearer plants		
	Investments accounted for using equity method		
	<b>Non-current financial assets</b>	<b>11401773</b>	<b>11879886</b>
	Non-current investments	1592254	1592254
	Trade receivables, non-current		
	Loans, non-current		498200
	Other non-current financial assets		
	<b>Total Non-current financial assets</b>	<b>1592254</b>	<b>2090454</b>
	Deferred tax assets (net)		
	Other non-current assets		
	<b>Total Non-current Assets</b>	<b>12994027</b>	<b>13970340</b>
2	<b>Current assets</b>		
	Inventories	4730185	7200886
	<b>Current financial assets</b>		
	Current investments	34937909	29936585
	Trade receivables, current	16823261	8215528
	Cash and cash equivalents	107895	251974
	Bank balance other than cash and cash equivalents	16874	6500088
	Loans, current	913522	736491
	Other current financial assets	5375138	5377578
	<b>Total current financial assets</b>	<b>58174599</b>	<b>51018244</b>
	Current tax assets (net)		
	Other current assets		
	<b>Total Current Assets</b>	<b>62904784</b>	<b>58219130</b>
3	Non-current assets classified as held for sale		
4	Regulatory deferral account debit balances and related deferred tax Assets		
	<b>TOTAL ASSETS</b>	<b>75898811</b>	<b>72189470</b>



/s/

EQUITIES AND LIABILITIES			
1	<b>Equity</b>		
	<b>Equity attributable to owners of Parent</b>		
	Equity share capital	29903000	29903000
	Other equity	32343097	30720893
	<b>Total Equity attributable to owners of Parent</b>	<b>62246097</b>	<b>60623893</b>
	Non controlling interest		
	<b>Total Equity</b>	<b>62246097</b>	<b>60623893</b>
2	<b>Liabilities</b>		
	<b>Non-current liabilities</b>		
	<b>Non-current financial liabilities</b>		
	Borrowing, non-current	1043920	849413
	Trade payables, non-current		
	Other non-current financial liabilities		
	<b>Total Non-current financial liabilities</b>	<b>1043920</b>	<b>849413</b>
	Provisions, non-current		
	Deferred tax liabilities (net)	593317	593317
	Deferred government grants, Non-current Other non-current liabilities		
	<b>Total Non-current liabilities</b>	<b>1637238</b>	<b>1442730</b>
	<b>Current liabilities</b>		
	<b>Current financial liabilities</b>		
	Borrowing, current	1049733	417537
	Trade payables, current	7648207	5616188
	Other current financial liabilities		
	<b>Total current financial liabilities</b>	<b>8697940</b>	<b>6033725</b>
	Other current liabilities	1793699	2932592
	Provisions, current	1523838	1156530
	Current tax liabilities (Net)		
	Deferred government grants, Current		
	<b>Total current liabilities</b>	<b>12015476</b>	<b>10122847</b>
3	Liabilities directly associated with assets in disposal group classified as held for sale		
4	Regulatory deferral account credit balances and related deferred tax liability		
	<b>Total Liabilities</b>		
	<b>Total Equity and Liabilities</b>	<b>75898811</b>	<b>72189470</b>

For, ISHITA DRUGS AND INDUSTRIES LIMITED



*Jagdish Agrawal*

JAGDISH AGRAWAL

MANAGING DIRECTOR

Place Ahmedabad

Date 13-Nov-18

DIN: 01031687



# PRATIK K KIKANI & ASSOCIATES

CHARTERED ACCOUNTANTS MRN: 180309 FRN:145950W  
PROPRIETOR: PRATIK KAUSHIKKUMAR KIKANI PAN: ATVPK1876E

To,  
The Board of Directors,  
Ishita Drugs & Industries Ltd.  
Ahmedabad.

## LIMITED REVIEW REPORT

We have reviewed the accompanying statement of unaudited financial results of **ISHITA DRUGS AND INDUSTRIES LTD** for the period ended **30<sup>th</sup> September, 2018** (The Statement) being submitted by the Company pursuant to the requirement of Regulation 33 of SEBI ( Listing of Obligations and Disclosure Requirements) Regulation,2015, read with SEBI Circular No.CIR/CFD/FAC/62/2016 dated 5<sup>th</sup> July, 2016. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Review of interim financial information performed by the independent auditor of the entity issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with Indian accounting standards prescribed under section 133 of Companies Act, 2013, read with relevant rules issued there under and another recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of SEBI ( Listing of Obligations and Disclosure Requirements) Regulation,2015, read with SEBI Circular No.CIR/CFD/FAC/62/2016 dated 5<sup>th</sup> July, 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For and on behalf of  
PRATIK KAUSHIKKUMAR KIKANI  
Chartered Accountants

*Kishori Pratik*  
CA Pratik Kaushikkumar Kikani  
Proprietor

MRN: 180309  
FRN: 145950W  
Date: 13/11/2018  
Place: Ahmedabad



For, PRATIK K. KIKANI & ASSOCIATES  
Chartered Accountants

*Kishori Pratik*  
Proprietor